Regina Holliday prepares her supplies for a day of painting. Photo by Maggie Starbard, NPR.

Regina Holliday has painted a mural on the side of a gas station in Washington DC to tell the story of a day in her husband Fred’s struggle with broken healthcare. At ge 39, Fred was diagnosed with stage IV kidney cancer.

The Obama administration has changed Federal policies on regulation of medical marijuana use under state law. During his presidential race last year, Barack Obama said that he intended to halt raids of medical marijuana facilities operating legally under state laws. Today, new Justice Department guidelines brought this change about.

The new guidelines order federal drug agents to stop arresting or charging patients, caregivers or suppliers who are dispensing, buying or using marijuana for medical purposes allowed by state law.

Eight-year-old Gavin Rodden was diagnosed recently with a rare childhood cancer, which began in his prostate.

Rhabdomyosarcoma (Rhab-do-my-o-sarcoma) is an aggressive form of cancer that starts in a muscle cell and may spread quite rapidly. In Gavin’s case the cancer has already spread from the prostate to his lungs. Possible treatments include surgery, radiation therapy, chemotherapy and options in clinical trials.

This little boy is facing challenges that any man might find overwhelming.

We feel some guys might like to add some big brother outreach to back up the support Gavin is already receiving from East Texans.

Scientists have identified seven new genetic variants that appear to be linked with increase risk of prostate cancer. Among these are four new “single-letter” genetic variants on one particular chromosome, called 8q24.

This chromosomal region has previously been associated with breast, colon, and bladder cancer. The discoveries identifying the four new genetic locations associated with prostate cancer on chromosome 8q24 were made by teams of independent scientists around the world. Three separate research papers on the discoveries are published in the online issue of Nature Genetics.

In one of the papers, Rosalind Eeles, from the London, UK Institute of Cancer Research laboratory (ICR) and colleagues in the Genetic Epidemiology Unit, University of Cambridge, report on the discovery of seven new prostate cancer susceptibility loci. In this video Dr. Eeles explains what her team found. She says they plan to take the results “into the clinic” to try to predict which men may need early testing for prostate cancer. Dr. Eeles says 8q is a “very interesting part of the genome for solid cancer risk.”

Brave New Films’ video Sick for Profit opens with a clip of a woman, Jo Joshua Godfrey, who says Cigna cut off her coverage by telling her she had nothing wrong with her, when they knew — as she did not — that her scans showed she had lung cancer.

I would go to CIGNA and they would tell me I had bronchitis and give me medicine and send me home. Then the CIGNA Director called me up and she told me that there was nothing wrong with me at all. I called the doctor, and I came with my film and my CAT scan and he just put it in, it took exactly thirty seconds. He told me, ‘You have cancer,’ and he said the reason CIGNA did not want to give you your records is they’ve known right way back for years that you have cancer and they’re not going to treat you.” Jo Joshua Godfrey.

the 4th C2 Academic Retreat (C2R) being organized jointly by the Canadian Urologic Oncology Group (CUOG) and the Canadian Urology Research Consortium (CURC) is scheduled for the weekend of September 25 to 27, 2009 at the fashionable hotel called W in Montreal.

According to UroToday, “this three-day educational event will include provocative ‘Town Hall’ sessions on the topics of Hormone Replacement and Cancer Risk, Prostrate Screening Controversies and the use of Robotic Technology in Surgery (Is it ready for prime time?).” “The line-up of topics and the caliber of presenters is unsurpassed in all the years we have been conducting these events,” says Dr. Laurence Klotz, Chair of the CURC and immediate past president of the Canadian Urology Association (CUA).

The Retreat allows the sponsoring (and often competing) pharmaceutical companies (i.e. Amgen AstraZeneca, Sanofi Aventis, GlaxoSmitKline, Merck Frosst, Novartis, Minoque Medical, Genesis Genomics, and Pfizer) to actively participate in the academic portion of the agenda.

The EPA should not permit mining operations based on regulatory loopholes and lax enforcement practices that have allowed mountain waterways to be treated as waste dumps. The people in Appalachia, like all Americans, have a right to clean streams, rivers, and drinking water — and it’s up to the EPA to look out for their interests. Today the agency fulfilled that duty, and now we expect the EPA to follow-up with the necessary actions to end — not to mend — the practice of mountain removal. Rob Perks, a blogger at the National Resources Defense Council , September 11, 2009.

People in Appalachia have lived and worked with coal for generations. Mining communities have endured countless struggles and tragedies associated with harsh conditions of mining underground and also with harsh environmental results of strip mining.

Since the 1970s, scientists, politicians and voters have debated economic, environmental and health effects of reliance on coal-fired energy. In 2006, Appalachians witnessed the Sago Mine underground disaster in West Virginia (photo, left), in which 13 men were trapped for two days and all but one lost their lives.

Now concerns are growing about about impact of the latest coal-mining method on water quality. This method is known as mountaintop removal.

Ohio scientists have demonstrated that diesel exhaust induces the growth of new blood vessels that send blood to supply to solid tumors. This is the first evidence of how exposure to diesel fumes can cause cancer.

The researchers found that more new blood vessels sprouted in mice exposed to diesel exhaust than did in mice exposed to clean, filtered air. The same changes happened in both healthy mice and in sick animals. This suggests, the scientists say, that previous illness isn’t required to make humans susceptible to the damaging effects of the diesel exhaust.

ZD4054 is a potential anti-cancer agent now in a clinical trials around the world for men with metastatic hormone refractory prostate cancer (HRPC) and for men with non-metastatic hormone refractory prostate cancer.

The trials are run by pharmaceutical company AstraZeneca, which makes ZD4054. These two distinct trials differ significantly in the level of therapy offered to men who do not receive the novel (new and not yet proven) trial drug.

The novel drug is a selective endothelin-A receptor antagonist (SERA) from the same family as atrasentan (brand name Xinlay) and YM598. Xinlay, which for a while looked quite promising, failed to prove effective in clinical trials for prostate cancer in 2005 and did not win FDA approval.

A study published in Clinical Cancer Research August 18 2009 reports that an extract of the Chinese herb Wedelia (a member of the Asteraceae, or sunflower family of plants) shrinks the androgen receptor and prostate cancer in male mice.

“Wedelia chinensis,” the authors write, “is a common ingredient of anti-inflammatory herbal medicines in Taiwan and southern China. Inflammation is involved in promoting tumor growth, invasion, and metastasis. This study aims to test the biological effects in vivo of W. chinensis extract on prostate cancer.”